ClinicalTrials.gg
Not yet recruitingNCT07542964TRANSFORMUpdated Apr 21, 2026

Transgender Analysis of Nephrological Studies Focused on Renal Metrics

An observational study in Kidney Disease, Kidney Injury and Transgender Individuals, sponsored by Amsterdam UMC, location VUmc. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Amsterdam UMC, location VUmc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Kidney Diseases with a site in Netherlands — 6 open to participants now, 10 under way, 5 of them phase 3. Kidney Diseases · Netherlands.

Started
2026
with 1 other
Observational
5 of 36
2 open now
Registered
35th of 36
by date

Among the 36 studies in Kidney Diseases with a site in Netherlands, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 35th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

6 of the 36 studies in Kidney Diseases with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Kidney Diseases with a site in Netherlands, or all of them as a file.
02

Study summary

This study investigates how sex hormones affect kidney function in people undergoing gender-affirming hormone therapy (GAHT). We know men have a faster progression of kidney disease. Earlier studies suggest that the female sex hormone estradiol may have a protective effect on kidney function while the male sex hormone testosterone may have the opposite effect. But the reasons why this happens remain unclear. By studying participants undergoing (GAHT) we gain insight into the mechanisms by which testosterone and estradiol influence the kidneys. People undergoing GAHT provide a unique chance to study how sex hormones interact with the kidneys. The results may help us to understand why men and women exhibit differences in kidney disease development. This study will include 30 men and 30 women, aged 18 to 40, who start GAHT. Participants will have three study visits, two of which will happen during their scheduled healthcare appointments. During the first visit, a screening will take place to check if patients can take part in the study. At study visits before and after one year of therapy, kidney function is measured, kidney MRI is performed, urine is collected and a small sample of fat tissue. Taking part in the study does not delay the start of GAHT.

Read the detailed description

Sex differences in kidney physiology are a vastly understudied area, despite known differences in sex-specific rates of chronic kidney disease. Kidney function decline is accelerated in men compared to women, suggesting a potential harmful role for testosterone. Transgender individuals undergoing hormone therapy provide a unique model to study the effects of gender affirming hormone therapy on kidney function and renal physiology. The central objectives of this study are to comprehensively assess the effects of gender affirming hormone therapy (GAHT; testosterone in transgender men or estradiol and an anti-androgen in transgender women) therapy on kidney function and physiology. This study is a prospective observational study. In total we will include 60 transgender individuals (30 transgender men and 30 transgender women) between 18-40 years old, scheduled to start GAHT. The primary endpoint is measured glomerular filtration rate (GFR) by iohexol clearance. Secondary endpoints include effects of GAHT on measures of intrarenal hemodynamic function including effective renal plasma flow (ERPF), proximal tubular function, insulin sensitivity and multiparametric kidney MRI (phase-contrast MRI [perfusion], arterial spin labeling [perfusion], BOLD imaging with a multi-echo spin-echo mapping R2* [oxygenation] and diffusion-weighted MRI [diffusion]). We will also isolate urinary tubuloids to further study the effect of sex hormones on kidney physiology and in these tubuloids we will assess whether the kidney protective effects are affected by sex hormones in vitro. Furthermore, endothelial cells will be harvested by J-wire, and single-cell RNA sequencing will be performed to investigate the transcriptional effects of GAHT in endothelial cells. And finally, we will look at adipose tissue gene expression.The burden for participants consists of three study visits, two of which will replace scheduled meetings that are a part of standard healthcare practice. In total, participants will receive one venipuncture and four intravenous cannulas, from which blood will be sampled (study total of 275 mL) and iohexol and p-aminohippurate will be administered to measure GFR and ERPF respectively. After measurement of kidney function, insulin sensitivity will be measured using a variable infusion of glucose and insulin (hyperinsulinemic euglycemic clamp). Patients will undergo kidney MRI which will take about 45 minutes; participants with claustrophobia are excluded. In addition, participants will be asked to collect a 24-hour urine sample on the days prior to the second and third study visit. Subcutaneous adipose tissue is collected by needle aspiration after local anesthesia. Finally, endothelial cells will be harvested. The total risk of negative effects for participants in the current study is considered low. The transgender population is a unique population in which the effects of exogenous cross-sex hormone administration can be studied. This study may provide additional data on the safety of hormone therapy in this population and may also lead to meaningful insights regarding the physiological effects of sex hormones on kidney function in humans that may help to understand observations from cohort studies which indicate differences in progression to kidney failure dependent on gender.

03

Conditions studied

  • Kidney Disease
  • Kidney Injury
  • Transgender Individuals

Browse trials for

Keywords

  • Transgender individuals
  • Kidney disease
  • Kidney injury
  • Gender affirming hormone treatment
  • Sex hormones
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The source population consists of adult patients with gender dysphoria, who are scheduled to start with GAHT in the Amsterdam University Medical Centre (AUMC) in Amsterdam. A total of 60 transgender individuals (30 transgender women, 30 transgender men) will be selected from this outpatient clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with gender dysphoria according to
  • Expected to start gender-affirming hormone treatment in the upcoming month

Exclusion criteria

Exclusion Criteria:

  • Current or prior use of gender-affirming hormone therapy
  • Participation in other studies
  • Concomitant use of medication (specifically: antihypertensive agents, products, antidepressants, antipsychotic agents)
  • Known kidney disease ( \< 60 ml/min; UACR > 2.5 mg/mmol)
  • Diabetes mellitus
  • A history of cardiovascular disease (myocardial infarction; cardiac surgery or revascularization, unstable angina, heart failure, , cerebrovascular disease, or a previously undiagnosed arrhythmia)
  • Known iodine-related allergies
  • Metal in the body (such as pacemaker, ICD, neurostimulator, cochlear implant, or other metal)
  • Pregnancy
  • Claustrophobia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Transgender males

    Individuals clinically scheduled to start GAHT with testosterone therapy

    Diagnostic Test: P-aminohippurate clearance study · Diagnostic Test: Iohexol infusion · Diagnostic Test: Hyperinsulinemic clamp

  • Transgender women

    Individuals clinically scheduled to start GAHT with estradiol and anti-androgen therapy

    Diagnostic Test: P-aminohippurate clearance study · Diagnostic Test: Iohexol infusion · Diagnostic Test: Hyperinsulinemic clamp

Interventions

  • Diagnostic testP-aminohippurate clearance study

    To measure effective renal plasma flow (ERPF), small doses of a substance called p-aminohippurate will be used

  • Diagnostic testIohexol infusion

    To measure glomerular filtration rate (GFR) iohexol clearance will be performed

  • Diagnostic testHyperinsulinemic clamp

    Glucose/insulin infusion to measure insulin sensitivity

06

What researchers measure

Primary outcomes

  1. Change in measured glomerular filtration rate (GFR)

    Time frame: Baseline, 12 months after start GAHT

Secondary outcomes

  1. Change in effective renal plasma flow (ERPF)

    Time frame: Baseline, 12 months after start GAHT

  2. Change in systemic hemodynamic function

    Time frame: Baseline, 12 months after start GAHT

  3. Change in insulin sensitivity

    Time frame: Baseline, 12 months after start GAHT

  4. Change in markers of tubular physiology

    Time frame: Baseline, 12 months after start GAHT

  5. Changes in multiparametric kidney MRI

    Including (phase-contrast MRI (perfusion), arterial spin labeling (perfusion), BOLD imaging with multi-echo spin-echo mapping R2\* (oxygenation) and diffusion-weighted (DW) MRI (diffusion)

    Time frame: Baseline, 12 months after start GAHT

  6. Changes in endothelial function

    Time frame: Baseline, 12 months after start GAHT

  7. Change in adipose tissue gene expression and adipose tissue biology

    Time frame: Baseline, 12 months after start GAHT

  8. Change in tubular effects of kidney protective therapies in vitro

    Time frame: Baseline, 12 months after start GAHT

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 100 non-industry observational studies under Kidney Diseases, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33. This study's planned 24 months is below that.

Counting every sponsor, half of 117 studies reached it within 59 months; a quarter within 31 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 21, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07542964
Collaborators
Dutch Kidney Foundation
Responsible party
Daniel van Raalte (Prof. Dr., Amsterdam UMC, location VUmc) — Principal investigator
First posted
Apr 21, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion